BioSpace News Archive

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced financial results for the fourth quarter and full year ended December 31, 2022.

Reflect Scientific Inc, a provider of ultra-low temperature freezers and chillers for the biotech, pharmaceutical, and cannabis industries, announced its financial results for the year ended December 31, 2022.

SWK Holdings Corporation announced that the Company will host a conference call and live audio webcast on Monday, April 3, 2023, at 10:00 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full year of 2022.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, PhD, will present at the World Vaccine Congress being held April 3 – 6 in Washington D.C.

Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced it has completed enrollment in its phase 2 study of imlifidase in Guillain-Barré Syndrome.

Tianlong, an innovative high-tech company specializing in molecular diagnostic products, has announced the global release of two new products, the GeneFlex Nucleic Acid Extractor and the Gentier mini+ Real-time PCR System.

Eledon Pharmaceuticals, Inc. reported results from the Company’s ongoing Phase 1b open-label trial evaluating tegoprubart in patients undergoing kidney transplantation at the World Congress of Nephrology, which is taking place March 30 to April 2, 2023.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the year ending December 31, 2022.

On March 30, 2023, Apollomics Inc., an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp.

Fennec Pharmaceuticals Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion and recommended granting a Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) – known as PEDMARK® in the U.S. – for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic, solid tumors.